Copyright
©The Author(s) 2015.
World J Hepatol. May 28, 2015; 7(9): 1287-1296
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1287
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1287
Figure 2 Safety and adverse events during triple therapy after liver transplantation.
Cumulative analysis of moderate and severe side effects related to the treatment period. TW: Treatment week.
- Citation: Herzer K, Papadopoulos-Köhn A, Achterfeld A, Canbay A, Piras-Straub K, Paul A, Walker A, Timm J, Gerken G. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol 2015; 7(9): 1287-1296
- URL: https://www.wjgnet.com/1948-5182/full/v7/i9/1287.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i9.1287